<DOC>
	<DOCNO>NCT02942602</DOCNO>
	<brief_summary>1 ) test HDL function comprehensively healthy diseased individual ; 2 ) evaluate test correlate cardiovascular risk , independent traditional risk factor ; 3 ) differentiate effect lipid-modifying antiatherosclerotic drug HDL function composition</brief_summary>
	<brief_title>Effect Lipid Modifying Drugs HDL Function Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>The patient meet 2013 American College Cardiology/American Heart Association criterion receive lipidlowering therapy Aged 20 Consent form sign pregnant lactating woman subject familial hypercholesterolemia uncontrolled hypertension DM Thyroid dysfunction Active liver disease ( transaminase bilirubin &gt; 1.5 x NL ) Serum creatinine &gt; 2 mg/dL Included clinical trial within 3 month use medication : fish oil , fibric acid derivative , niacin , systemic corticosteroid , thiazolidinedione</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>